Early Detection
leads to curative treatment
What is Prenostics?
Prenostics applies technology to detect the earliest stages of cancer, long before any other method can diagnose cancer today.
Prenostics finds cancer at its earliest stages.
For the first time, Prenostics makes it possible to see and measure what was once invisible and immeasurable - cells in the earliest cancer stages, stages 0-2 - via a simple blood test.
Sarah Blagden, Professor of Experimental Oncology
at the University of Oxford, Founder and CSO of Prenostics
Prenostics is changing the way the world thinks about cancer detection.
Anyone faced with a cancer diagnosis questions whether it could have been prevented or caught earlier.
While screening programmes are effective in finding some cancers early, the majority are not detectable through screening.
Prenostics offers an alternative: a blood test that provides early cancer warning.
How early?
Prenostics can find stage 0-2 cancers, two to three years before active disease shows up on a routine scan or test by current methods.
Prenostics is a step-change in healthcare, detecting cancer earlier, leading to curative treatments.
.avif)
Prenostics enables early detection
Prenostics detects cancer at its earliest stages, stage 0-2, earlier than any other detection method currently available and leading to curative treatment. The initial clinical targets are for women at elevated risk of ovarian cancer and for people with lung nodules that have an indeterminate clinical profile.
Less invasive treatment.
The Prenostics Score complements existing screening pathways and removes the uncertainty of equivocal results. This reduces anxiety and ensures medical interventions are conducted faster in those at greatest cancer risk.
No rushed decisions.
When it comes to cancer, early detection grants an opportunity to prevent the disease, providing more time, more options and ultimately, better outcomes.
Work with us
Whether you are a doctor, researcher, or investor, we’d love to work with you.